Trial Profile
Treatment of Congenital Factor VII Deficiency. A Prospective Observational Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Factor VII deficiency
- Focus Therapeutic Use
- Acronyms F7CONDEF
- Sponsors Novo Nordisk
- 15 Apr 2014 New trial record